Tag: Verquvo

Over 6.5 million adults in the United States are living with heart failure, a number projected to rise significantly. For these patients, the critical question is often, **what is the new pill for congestive heart failure** that can offer new hope and improved quality of life?

While both riociguat (Adempas) and vericiguat (Verquvo) belong to the same class of soluble guanylate cyclase (sGC) stimulators, they are approved for distinctly different conditions. Choosing the 'better' drug is not a simple comparison, but rather an assessment of which medication is appropriate for a patient's specific diagnosis.